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Abstract
In vitro hypoxic preconditioning (HP) of mesenchymal stem cells (MSCs) could ameliorate their viability and tissue repair
capabilities after transplantation into the injured tissue through yet undefined mechanisms. There is also experimental
evidence that HP enhances the expression of both stromal-derived factor-1 (SDF-1) receptors, CXCR4 and CXCR7, which are
involved in migration and survival of MSCs in vitro, but little is known about their role in the in vivo therapeutic effectiveness
of MSCs in renal ischemia/reperfusion (I/R) injury. Here, we evaluated the role of SDF-1-CXCR4/CXCR7 pathway in regulating
chemotaxis, viability and paracrine actions of HP-MSCs in vitro and in vivo. Compared with normoxic preconditioning (NP),
HP not only improved MSC chemotaxis and viability but also stimulated secretion of proangiogenic and mitogenic factors.
Importantly, both CXCR4 and CXCR7 were required for the production of paracrine factors by HP-MSCs though the former
was only responsible for chemotaxis while the latter was for viability. SDF-1a expression was upregulated in postischemic
kidneys. After 24 h systemical administration following I/R, HP-MSCs but not NP-MSCs were selectively recruited to ischemic
kidneys and this improved recruitment was abolished by neutralization of CXCR4, but not CXCR7. Furthermore, the
increased recruitment of HP-MSCs was associated with enhanced functional recovery, accelerated mitogenic response, and
reduced apoptotic cell death. In addition, neutralization of either CXCR4 or CXCR7 impaired the improved therapeutic
potential of HP-MSCs. These results advance our knowledge about SDF-1-CXCR4/CXCR7 axis as an attractive target pathway
for improving the beneficial effects of MSC-based therapies for renal I/R.
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Introduction
Renal ischemia/reperfusion (I/R) injury is the most common
cause for acute kidney injury (AKI) which affects both native and
transplanted kidneys and is associated with high morbidity and
mortality [1,2]. A large number of studies have focused on the
endogenous and exogenous mechanisms of kidney repair after
schemic/hypoxic injury [3–6]. Interestingly, a recent clinical study
suggested that nocturnal hypoxia was associated with accelerated
loss of kidney function in patients with obstructive sleep apnea
syndrome [7]. In the last few years, several studies have shown that
mesenchymal stromal cells (MSCs) can prevent or attenuate
ischemic tissue injury, possibly by paracrine/autocrine mecha-
nisms or trans-differentiation into local cell types [5,6,8–13]. When
administered systemically, however, only a small proportion of the
infused MSCs homing to the ischemic tissue, whereas the majority
of cells were found entrapped in other organs including lungs
[10,14,15]. Furthermore, due to the local hypoxia, oxidative stress
and inflammation in the targeted ischemic tissue, the retention of
transplanted MSCs is poor and the low cell survival reduces the
therapeutic effects [16]. Thus, it is crucial to find techniques which
can enhance the chemotaxis and retention of the implanted MSCs
to maximize the effectiveness of MSC-based therapy.
The ischemic tissue produces numerous cytokines, chemokines,
secreted proteins and growth factors that may influence organ-
specific and stem cell-mediated repair [17–22]. Several studies also
provided evidences for a critical role of hypoxia-inducible factors
in renal epithelial differentiation and repair [23–26]. A number of
studies have proven that chemokine stromal cell-derived factor-1
(SDF-1, also known as CXCL12) is critical for the process
involving stem/progenitor cell chemotaxis and organ-specific
homing in ischemic tissue through interaction with its cognate
receptor CXC chemokine receptor 4 (CXCR4) on the surface of
stem/progenitor cells [27–31]. Although CXCR4 is highly
expressed in MSCs within the bone marrow, its expression is
markedly reduced during ex vivo expansion of MSCs [32,33]. This
could decrease the ability of implanted MSCs to respond to
homing signals emanated from the ischemic tissue [34]. Several
reports have showed that short-term exposure of MSCs to hypoxia
could upregulate CXCR4 expression [35–38]. We have previously
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34608reported that CXCR7, a novel receptor for SDF-1, is also
upregulated by sub-lethal hypoxic preconditioning (HP) of
cultured MSCs [39]. However, the effect of both SDF-1 receptors
on paracrine actions of MSCs still remains unknown; especially,
the role of the SDF-1-CXCR4/CXCR7 axis in the therapeutic
effects of MSCs for renal I/R has not been evaluated in vivo.
In this study, we demonstrate for the first time that HP
markedly augments chemotaxis, viability and paracrine actions of
MSCs in vitro and thus enhances the benefit of MSC-based therapy
for renal I/R through interaction of SDF-1 with CXCR4 and
CXCR7.
Results
HP upregulates expression of SDF-1a and its receptors,
CXCR4 and CXCR7, in MSCs
Preliminary experiments showed that the viability and growth of
MSCs were not adversely affected by 48 h of hypoxia (3% O2)
(data not shown). The mRNA level and protein expression of
CXCR4 and CXCR7 are high in bone marrow mononuclear
cells, but low or undetectable in MSCs at passage 1 to 3 (Fig. 1A
and B). The exposure of MSCs at passage 3 to hypoxia for 24 h
upregulated the expression of SDF-1a and its receptors (Fig. 1A
and B). To examine cell surface expression of CXCR4 and
CXCR7, flow cytometry (FCM) was performed and revealed that
number of either CXCR4- or CXCR7-positive cells was
significantly higher in MSCs exposed to hypoxia for 24 h, 36 h
and 48 h than that for 0 h, respectively (Fig. 1C). Furthermore,
enzyme-linked immunosorbent assay (ELISA) analysis showed HP
caused a time-dependent increase of SDF-1a protein level,
reaching maximal at 24 h to 48 h after HP (Fig. 1D).
SDF-1-CXCR4 axis is required for MSC chemotaxis
In accord with our previous study [39], the present study
demonstrated that HP significantly increased MSC chemotaxis in
response to SDF-1a, and this increased chemotaxis was blocked
obviously by an anti-CXCR4 antibody, but not by an anti-
CXCR7 antibody (Fig. 2A). To further support this possibility,
NP-MSCs where both CXCR4 and CXCR7 expression was
undetectable were transfected with sense expression vectors of
pORF9-mCXCR4 or pORF9-mCXCR7, or empty vector
pORF9, respectively. Numerous clones showing increased
CXCR4 or CXCR7 expression were screened by the level of
expression of either CXCR4 or CXCR7 and confirmed by
western blots after 24 h and 48 h of transfection (Fig. 2B).
Following transfection, cells were subjected to 24 h of normoxia
followed by 6 h of 1–100 ng/ml SDF-1a treatment. As expected,
there was a dose-dependent increase in the chemotaxis in response
Figure 1. Effects of HP on the expression of SDF-1a, CXCR4, CXCR7 in MSCs. (A) Semiquantitative RT-PCR was used for the analysis of SDF-
1a, CXCR4 and CXCR7 mRNA levels in MSCs. GAPDH was used as a control. Lane 1 indicates bone marrow mononuclear cells (BMMCs); lanes 2 to 4,
MSC cultures at passage 1 to 3; and lane 5, MSCs at passage 3 and exposed to hypoxia (3% O2) for 24 h. (B) Western blot analysis was performed to
detect CXCR4, CXCR7 and SDF-1a protein expression. b-actin was used as a control. Lanes 1 indicates BMMCs; lanes 2 to 5, MSC cultures at passage 1
to 4; and lane 6, MSCs at the third passage to hypoxia for 24 h. (C) FCM was used to detect extracellular expression of CXCR4 or CXCR7 in MSCs
exposed to the indicated periods of hypoxia. *P,0.05, vs 0 h. (D) ELISA analysis was performed to determine production of SDF-1a from MSCs
exposed to the indicated periods of hypoxia. *P,0.05, vs 0 h.
doi:10.1371/journal.pone.0034608.g001
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transfected and empty vector-transfected cells (Fig. 2C). Further-
more, as shown in Fig. 2D through 4F, SDF-1a stimulation
(50 ng/ml) had no effect on the chemotaxis in response to SDF-1a
and the expression of CXCR4 and CXCR7 in both HP-MSCs
and NP-MSCs.
SDF-1-CXCR7 axis is required for MSC viability
Since H2O2 has previously been shown to be a critical mediator
of hypoxia/reoxygenation- or ischemia/reperfusion-induced cell
death [40], we investigated the effect of HP on H2O2-induced
cytotoxicity of MSCs. To this goal, standard cytotoxicity tests,
including MTT assay for mitochondrial viability, propidium
iodide (PI)-based cell viability, and LDH assay for membrane
damage, were performed. The results of cell viability assays by an
automated NucleoCounter (Fig. 3A1) revealed no apparent
cytotoxicity in HP-MSCs compared with that in NP-MSCs under
normal culture conditions. H2O2 treatment increased the
cytotoxicity in both NP-MSCs and HP-MSCs, however, the
increase was more dramatic in NP-MSCs than in HP-MSCs
(Fig. 3A1, B1 and C1). Pretreatment of HP-MSCs with an anti-
CXCR7 antibody but not with an anti-CXCR4 antibody
completely increased the H2O2-induced cytotoxicity in compar-
ison with cells treated with the respective isotype matched control
Figure 2. Effects of SDF-1-CXCR4/CXCR7 pathway on MSC chemotaxis in vitro. (A) The chemotaxis in response to SDF-1a (10 ng/ml for
12 h) was performed in the NP-MSCs and HP-MSCs treated with a neutralizing anti-CXCR4 antibody, an anti-CXCR7 antibody, and the respective
isotype-matched control antibodies. *P,0.05, vs NP-MSCs;
{P,0.05, vs the respective isotype-matched control antibodies. (B) NP-MSCs were
transiently overexpressed with CXCR4 using pORF9-mCXCR4 vector or with CXCR7 using pORF9-mCXCR7 vector (n=6). A negative control empty
(pORF9-MCS) vector was used. (C) The transfected cells were subjected to chemotaxis in response to the indicated concentrations of SDF-1a for 12 h.
*P,0.05, vs the empty vector. (D and E) Western blot analysis (D) and FCM (E) were performed to determine the intracellular and extracellular
expression of both CXCR4 and CXCR7 in the cells treated with or without SDF-1a (50 ng/ml for 60 min). (F) The chemotaxis in response to SDF-1a was
performed in the cells treated with or without SDF-1a.
doi:10.1371/journal.pone.0034608.g002
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cytotoxicity was significantly decreased in CXCR7-transfected
NP-MSCs compared with the CXCR4-transfected and empty
vector-transfected cells (Fig. 3A3, B3 and C3).
In addition, the role of SDF-1a on H2O2-induced cytotoxicity
of MSCs was also evaluated. Addition of SDF-1a (50 ng/ml) to
the culture had no effect on cell viability and LDH release of NP-
MSCs under H2O2 culture conditions (Fig. 3A1, B1 and C1).
However, treatment with SDF-1a markedly protected HP-MSCs
against H2O2 when compared with non SDF-1a treatment
(Fig. 3A1, B1 and C1). Importantly, this SDF-1a-induced
protection for HP-MSCs was obviously blocked by an anti-
CXCR7 antibody, but not by an anti-CXCR4 antibody (Fig. 3A2,
B2 and C2). Furthermore, transfection of CXCR7 markedly
protected NP-MSCs against H2O2, as indicated by SDF-1a-
induced increase in nuclear/mitochondrial viability and decrease
in LDH release when compared with transfection of CXCR4- or
empty vector (Fig. 3A3, B3 and C3).
Figure 3. Effects of SDF-1-CXCR4/CXCR7 pathway on H2O2-induced cytotoxicity in MSCs. The standard cytotoxicity tests, including
propidium iodide (PI)-based cell viability (A1–A3), MTT assay for mitochondrial viability (B1–B3), LDH assay for membrane damage (C1–C3), were
performed. (A1, B1, and C1) MSCs were incubated in H2O2-conditioned media (250 mM) added with or without SDF-1a (50 ng/ml) for 6 h. The cells
incubated in absence of both H2O2 and SDF-1a were used as control. A1 and C1: *P,0.05, vs NP-MSCs;
{P,0.05, vs Control;
{P,0.05, vs H2O2. B1:
*P,0.05, vs NP-MSCs;
{P,0.05, vs Non-SDF-1. (A2, B2, and C2) Prior to H2O2 treatment, HP-MSCs were treated with a neutralizing anti-CXCR4
antibody, an anti-CXCR7 antibody, and the respective isotype-matched control antibodies, respectively. *P,0.05, vs the respective isotype-matched
control antibodies;
{P,0.05, vs non-SDF-1. (A3, B3, and C3) Prior to H2O2 treatment, NP-MSCs were transiently overexpressed with CXCR4 using
pORF9-mCXCR4 vector or with CXCR7 using pORF9-mCXCR7 vector. *P,0.05, vs empty vector;
{P,0.05, vs Non-SDF-1.
doi:10.1371/journal.pone.0034608.g003
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required for MSC paracrine actions
We first determined the effects of HP on MSCs-secreted
proangiogenic and mitogenic factors. We found that 24 h of
hypoxia significantly increased MSC-secreted vascular endothelial
growth factor (VEGF), b-fibroblast growth factor (b-FGF), insulin-
like growth factor 1 (IGF-1), and hepatocyte growth factor(HGF)
compared with normoxia (Fig. 4A). Furthermore, the production
of these factors in the presence of SDF-1a was enhanced markedly
in HP-MSCs but only slightly in NP-MSCs (Fig. 4A).
Next, we wanted to determine the role of CXCR4 and CXCR7
in MSC paracrine actions. As shown in Fig. 4B and 4C, HP-
induced secretion of growth factors was completely abolished by
blocking either CXCR4 receptor with an anti-CXCR4 antibody
or CXCR7 receptor with an anti-CXCR7 antibody. Contrarily,
the secretion of these factors was significantly increased in
CXCR4- or CXCR7-transfected NP-MSCs compared with the
empty vector-transfected cells (Fig. 4D).
SDF-1a expression is upregulated in postischemic kidneys
We assessed SDF-1a expression in the kidney obtained from
mice treated with either sham or I/R surgery. Immunohisto-
chemistry staining showed that SDF-1a was extensively expressed
in the cytoplasm of renal tubules cells in I/R-AKI mice, but only
sporadically expressed in sham-operated kidneys (Fig. 5A). SDF-
1a appeared to be increased within the first 24 h of I/R, peaked at
48 h and rapidly downregulated in the subsequent days till day 7
after injury to the level comparable to that observed in sham-
operated kidneys (Fig. 5A). In addition, incubation with secondary
antibody alone did not result in any staining (data not shown).
Moreover, similar results of SDF-1a protein levels in the kidney
from I/R-AKI mice were also observed by ELISA (Fig. 5B).
HP-MSCs migrate toward hypoxia/reoxygenation-
damaged renal tubule epithelial cells in vitro
Primary renal tubule epithelial cells (TECs) from 1–2-week old
C56BL/6 mice were exposed to hypoxia/reoxygenation. This
procedure led to a 270% increase of SDF-1a protein level compared
to that of baseline as determined by ELISA (Fig. 6A). HP-MSCs
expressing CXCR4 and CXCR7 in the upper chamber of transwell
system showed enhanced chemotaxis toward the hypoxia/reoxy-
genation-damaged monolayer of tubular cells in the lower chamber
when compared to that observed with undamaged cells (Fig. 6B).
Importantly, blocking of CXCR4 but not CXCR7 significantly
decreased this chemotaxis toward damaged TECs (Fig. 6B).
HP increases the in vivo homing of transplanted MSCs to
ischemic kidneys
To validate the homing of MSCs to the target tissue, the cells were
radioactively labeled with
111Indium-oxine and then systemically
administered via tail vein into I/R-AKI mice. To facilitate
comparisons, the specific radioactivity of each organ was adjusted
by the half-life of
111Indium-oxine (2.8 days) and calculated as the
percentage of injected dose per gram tissue (%ID/g) and percentage
Figure 4. Effects of SDF-1-CXCR4/CXCR7 pathway on MSC paracrine actions. ELISA was performed to determine production of VEGF, b-
FGF, IGF-1 and HGF from MSCs stimulated by hypoxia (3% O2) or/and SDF-1a (50 ng/ml). The cells stimulated by neither hypoxia nor SDF-1a were
used as control. (A) MSCs were stimulated with hypoxia or/and SDF-1a.* P,0.05, vs control;
{P,0.05, vs SDF-1;
{P,0.05, vs hypoxia. (B and C) The HP-
MSCs stimulated with or whthout SDF-1a were treated with an anti-CXCR4 antibody (B), an anti-CXCR7 antibody (C), and the respective isotype-
matched control antibodies. *P,0.05, vs IgG2B (B) or IgG (C);
{P,0.05, vs aCXCR4 (B) or aCXCR7 (C);
{P,0.05, vs SDF-1+IgG2B (B) or SDF-1+IgG (C). (D)
NP-MSCs were transiently overexpressed with CXCR4 using pORF9-mCXCR4 vector or with CXCR7 using pORF9-mCXCR7 vector. *P,0.05, vs empty
vector;
{P,0.05, vs pORF9-mCXCR4 vector.
doi:10.1371/journal.pone.0034608.g004
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radioactivity of kidneys was observed between HP-MSC-transplan-
tated (8.461.7%ID/g) and NP-MSC-transplantated mice
(6.461.4%ID/g) 3 h after infusion (Fig. 6C). Meanwhile, the uptake
of radioactively labeled MSCs was restricted primarily to the lungs
[(151611)%ID/g and (20.961.7)%ID/organ]. 24 h after MSC
infusion, radioactively labeled MSCs were lost from the lungs
[(2965)%ID/g and (4.160.8)%ID/organ] and redistributed to
organs including kidneys, spleen and liver (Fig. 6D and E). In the
meantime, the amount of HP-MSCs in the ischemic kidneys was 2.5
times greater than that of NP-MSCs. In contrast, MSC accumulation
in other organs did not differ between HP-MSC-transplantated and
NP-MSC-transplantated mice. On day 3 after infusion, kidney
uptake of radioactively labeled HP-MSCs with decay correction was
not significantly different from that on day 1 after infusion; however,
kidney uptake of radioactively labeled NP-MSCs with decay
correction dropped to 42.869.6% of baseline (Fig. 6C). The evidence
that the kidney uptake of radioactively labeled MSCs in HP-MSC-
transplantated animals and the lack of uptake in the kidneys in NP-
MSC-transplantated animals at 5 to 14 days after infusion suggests
that this difference is likely due to NP-MSC loss in injured kidneys.
Neutralization of CXCR4, but not of CXCR7, impairs the
increased homing capability of HP-MSCs
To further investigate the role of SDF-1-CXCR4 and/or
CXCR7 interaction in the in vivo homing of HP-MSCs to ischemic
kidneys, the
111Indium-labeled cells before transplantation were
pretreated with a neutralizing anti-CXCR4 antibody, an anti-
CXCR7 antibody, or their isotype-matched control antibodies,
respectively. At 3 hours to 14 days after cell infusion, the kidney
uptake of radioactively labeled HP-MSCs pretreated with an anti-
CXCR7 antibody and control cells did not vary significantly
(Fig. 6F). However, an obvious decrease in kidney uptake of
radioactively labeled HP-MSCs pretreated with an anti-CXCR4
antibody was observed relative to that of cells pretreated with its
isotype-matched control IgG2B antibody at 1 to 7 days after
transplantation (Fig. 6F).
HP improves the therapeutic potential of MSCs for
treatment of I/R-AKI
24 h after surgery (i.e. immediately after MSC transplantation),
renal function was identically aggravated in animals designated to
receive HP-MSCs, NP-MSCs or vehicle treatment, as assessed by
blood urea nitrogen (BUN) and serum creatinine (Scr) levels
(Fig. 7A and B). Administration of NP-MSCs improved the renal
function in animals at days 3 and 7 after transplantation,
compared with that in vehicle-treated animals (Fig. 7A and B).
However, HP-MSC-treated animals had significantly lower BUN
and Scr levels at 24 h after infusion compared with both vehicle-
or NP-MSC-treated animals, and the renal function was restored
to normal levels at 3 days after transplantation (Fig. 7A and B).
To further substantiate above-mentioned heartening results, the
histologic examinations including histological score of kidney
(HSK), PCNA and TUNEL staining were evaluated immediately
or at days 1, 3, and 7 after transplantation. As expected, compared
with control kidneys from vehicle-treated mice, kidneys from
either HP-MSC- or NP-MSC-treated mice had significantly
reduced HSK, increased number of PCNA-positive cells, and
decreased number of apoptotic cells on TUNEL assay (Fig. 7C
through 7E). Interestingly, 24 h after cell infusion, the number of
PCNA-positive cells in kidneys from HP-MSC-treated mice was
significantly increased compared with that from both vehicle-(+11-
fold) or NP-MSC-(+5-fold) treated mice (Fig. 7D). The increase in
renal cell survival following MSC administration was confirmed by
measure of apoptosis using TUNEL analysis. One, three and seven
days after intravenous administration of MSCs, the number of
apoptotic renal cells detected at the ischemic kidneys was
significantly lower in HP-MSC-treated animals than in NP-
MSC-treated animals (Fig. 7E).
Neutralization of either CXCR4 or CXCR7 impairs the
improved therapeutic potential of HP-MSCs
ToassesswhethertheSDF-1-CXCR4/CXCR7axiswasinvolved
in the therapeutic potential of HP-MSCs, the cells were injected into
the tail vein of I/R-AKI mice after pretreatment with a neutralizing
anti-CXCR4 antibody, or an anti-CXCR7 antibody, or their
respective isotype-matched antibodies. At day 1 after cell infusion,
mice implanted with HP-MSCs pretreated with either anti-CXCR4
or anti-CXCR7 antibody had significantly higher BUN and Scr
levels(Fig. 7F and G), HSK (Fig. 7H), as well as number of apoptotic
cells in TUNEL assay (Fig. 7J) compared with mice implanted with
cells pretreated with theirs respective isotype-matched antibodies.
Figure 5. SDF-1a is upregulated in the kidney of I/R-AKI mice.
(A) Representative micrographs of immunohistochemistry for SDF-1a in
the kidneys from mice affected by IR-AKI days 1, 2 and 7 after I/R. The
kidney sections from mice 24 h after sham surgery were used as control
(upper left panel). Original magnification 6200. (B) The kidney cortex
lysates from mice affected by sham surgery or I/R-AKI were analyzed by
ELISA to determine SDF-1a protein expression at the indicated periods
of post-surgery time. *P,0.05, vs Sham.
doi:10.1371/journal.pone.0034608.g005
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or anti-CXCR7 antibody significantly reduced the number of
PCNA-positive cells in kidneys from I/R-AKI mice (Fig. 7I).
Discussion
The present study found for the first time that HP increased the
chemotaxis, viability and paracrine actions of MSCs in vitro via a
mechanism that is dependent, at least in part, on SDF-1-CXCR4/
CXCR7 pathway. When administered systemically, the HP-MSCs
homed to the ischemic kidney more efficiently than NP-MSCs,
which led to significantly improved renal function, accelerated
mitogenic response, and reduced cell apoptosis. Importantly, these
in vivo effects were largely abolished by either CXCR4 or CXCR7
inhibition, indicating that the in vivo benefits of HP are also
mediated by the SDF-1-CXCR4/CXCR7 axis (Fig. 8).
Although MSCs are able to withstand hypoxia for up to a few
days by upregulating survival pathways and increasing glycolytic
metabolism [41], they need to survive longer for maintaining a
long-term, effective MSC-based therapy in ischemic tissue. Short-
term exposure of MSCs to hypoxia can significantly enhance their
viability in vitro and in vivo, and thus improve their tissue repair
capabilities after transplantation into the ischemic tissue
[38,42,43]. HP can enhance the paracrine/autocrine effects of
MSCs by altering trophic factor release [38,43–45] and it also
plays an critical role in recruiting MSCs to the sites of injury in vivo
by upregulating the membrane markers associated with migration
and homing of MSCs [35–37,46]. A selective in vivo expression of
chemokine SDF-1 in ischemic tissue in direct proportion to
reduced oxygen tensions has been confirmed [46–49]. Our data
also demonstrated that SDF-1a is upregulated in the ischemic
kidneys within hours of I/R and remains elevated for several days.
The interaction of locally produced SDF-1 and its receptor
CXCR4 expressed on the MSC surface plays an crucial role in the
homing of transplanted cells [35,46,47,50,51]. However, culture-
expanded MSCs progressively downregulate CXCR4 expression
and lose their ability to migrate toward the SDF-1 gradient in the
ischemic tissue [32,33,52]. Our previous study reported HP-
induced expression of CXCR4 and CXCR7, and the role of both
SDF-1 receptors in enhanced migration, adhesion and survival of
HP-MSCs in vitro [39]. Thus, we used HP as a strategy to enhance
the homing of systemically delivered MSCs to the ischemic kidney.
Here, we further investigated the effects of SDF-1-CXCR4/
CXCR7 axis on the homing and the therapeutic outcome of
MSCs in vivo.
Figure 6. The role of SDF-1-CXCR4/CXCR7 pathway on the homing of HP-MSCs toward ischemic kidneys. (A) ELISA analysis was
performed to determine production of SDF-1a from primary TECs exposed to hypoxia/reoxygenation in vitro. The cells without hypoxia/
reoxygenation stimulation were used as control. *P,0.05, vs control. (B) The chemotaxis in response to hypoxia/reoxygenation-damaged primary
TECs was performed in HP-MSCs treated with a neutralizing anti-CXCR4 antibody, an anti-CXCR7 antibody, and the respective isotype-matched
control antibodies, respectively. *P,0.05, vs control;
{P,0.05, vs the respective isotype-matched control antibodies. (C) The kidney uptake of
111Indium-labeled NP-MSCs and HP-MSCs was measured from 3 hours to 14 days after systemic administration into I/R-AKI mice. The specific
radioactivity of each organ was expressed as the percentage of injected dose per gram tissue (%ID/g) after being adjusted by the half-life of
111Indium. *P,0.05, vs the respective isotype-matched control antibodies. (D and E) The uptake of
111Indium-labeled NP-MSCs and HP-MSCs in
different organs from I/R-AKI mice was measured 24 h after infusion. *P,0.05 vs NP-MSCs;
{P,0.05 vs Kidney. (F) The kidney uptake of
111Indium-
labeled NP-MSCs and HP-MSCs was measured from 3 hours to 14 days after infusing cells pretreated with a neutralizing anti-CXCR4 antibody, an anti-
CXCR7 antibody and the respective isotype-matched control antibodies, respectively. *P,0.05, vs the respective isotype-matched control antibodies.
doi:10.1371/journal.pone.0034608.g006
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chemotaxis, viability and paracrine actions of MSCs in vitro.T o
this end, the HP-MSCs that had markedly upregulated expression
of CXCR4 and CXCR7 were pretreated with the neutralizing
antibody against CXCR4 or CXCR7 to block their functions, and
NP-MSCs that did not have detectable CXCR4 and CXCR7
expression were transfected with sense expression vector of
CXCR4 or CXCR7 for upregulating these genes. The function
blockage of CXCR4 but not CXCR7 in HP-MSCs suppressed the
chemotactic response to SDF-1a, and CXCR4 overexpression
increased this chemotaxis of NP-MSCs, suggesting that only SDF-
1a-CXCR4 axis is responsible for the chemotaxis of MSCs.
Otherwise, our study also found that, at least in MSCs, H2O2-
induced cell apoptosis can be reverted by HP, and this HP-
induced survival process is mediated by CXCR7, but not by
CXCR4. Overexpression of CXCR7 but not of CXCR4 also
reverted H2O2-induced cell apoptosis of NP-MSCs, suggesting
that only SDF-1a-CXCR7 axis is responsible for the viability of
MSCs in vitro. In addition, the enhanced secretion of VEGF, b-
FGF, IGF-1 and HGF of MSCs by HP was inhibited by blocking
either CXCR4 or CXCR7, and overexpression of either CXCR4
or CXCR7 markedly increased paracrine actions of NP-MSCs,
suggesting that not only the SDF-1-CXCR4 interaction but also
the binding of SDF-1 to CXCR7 were required for the paracrine
actions of MSCs.
Interestingly,the results of this study alsoclearly demonstrate that,
at least in NP-MSCs, SDF-1a preconditioning has no effect on the
expression of CXCR4 and CXCR7, in vitro chemotaxis, viability and
paracrine actions. However, SDF-1a preconditioned HP-MSCs are
markedly protected againstH2O2, andthisSDF-1a-induced survival
process is mediated by CXCR7, but not by CXCR4. Similarly,
SDF-1a induced significant increase in the viability of CXCR7-
transfected but not of CXCR4-transfected NP-MSCs under H2O2
culture conditions. Furthermore, SDF-1a also markedly increased
the secretion levels of VEGF, b-FGF, IGF-1 and HGF in HP-MSCs
and in either CXCR4- or CXCR7-transfected NP-MSCs. These
data suggestthe roleof autocrine SDF-1a underhypoxiaand further
support the possibility that CXCR4 and CXCR7 play an essential,
but differential role in regulating chemotaxis, viability and paracrine
actions of MSCs in vitro.
In agreement with observations from in vitro chemotaxis assay,
HP can enhance the homing capacity of MSCs toward the injured
kidney in I/R-AKI mice, and this improved capacity is
significantly reduced by neutralization of CXCR4, but not of
CXCR7. Furthermore, significantly greater numbers of intrave-
nously infused HP-MSCs were homed in the ischemic kidneys
than that of NP-MSCs, leading to significantly improved renal
function, accelerated mitogenic response, and reduced HSK and
apoptotic index. Therefore, that systemic administration of HP-
MSCs that have significantly higher expression of CXCR4 and
CXCR7 than NP-MSCs may be a useful noninvasive therapy to
promote renal repair after I/R. Importantly, these beneficial
effects of HP-MSCs on renal tissue regeneration following I/R are
largely abolished by a neutralization of either CXCR4 or
CXCR7, indicating that SDF-1-CXCR4/CXCR7 axis qualifies
as an attractive target for MSC-based therapies. These findings
provide new insights into the role of SDF-1-CXCR4/CXCR7 in
HP-MSCs for regenerative medicine.
Materials and Methods
Ethics Statement
C57BL/6 mice were provided by the Experimental Animal
Center of the Fourth Military Medical University (Xi’an, China)
and Medical College of Xi’an Jiaotong University (Xi’an, China).
This study was carried out in strict accordance with the Guidelines
on the Care and Use of Laboratory Animals issued by the Chinese
Council on Animal Research and the Guidelines of Animal Care.
All procedures involving animals were approved by the Institu-
tional Animal Care and Use Committees of both the Fourth
Military Medical University and the Xi’an Jiaotong University. All
efforts were made to minimize animals’ suffering and to reduce the
number of animals used.
Isolation and culture of MSCs
MSCs were isolated from C57BL/6 mice as previously
described [39]. Briefly, femurs and tibiaes were prepared from
4–6-week-old male mice. The marrow was extruded with L-
DMEM (Gibco, Grand Island, NY, USA) and cultured in L-
DMEM containing 10% fetal bovine serum (FBS) and 1%
antibiotic/antimycotic solution (Gibco). After 24 h, the nonad-
herent cells were removed by replacing the medium. Adherent
MSCs had a typical spindle-shaped appearance and were used at
passage 3. For characterization of mouse MSCs, cultured cells
were subjected to flow cytometry using CD34, CD45, CD90 and
CD105 markers (BD Pharmingen, San Diego, CA, USA), and
were identified as CD90
+/CD105
+ and CD34
2/CD45
2cells.
HP of MSCs
MSCs were cultured in a hypoxia chamber incubator (catalog
No. 27310; StemCell Technologies, Vancouver, BC, Canada) at
37uCi n3 %O 2,5 %C O 2 and 92% N2 for 24 h, and these MSCs
were named as hypoxia-preconditioned MSCs (HP-MSCs).
Normoxia-preconditioned (for 24 h in 95% air, 5% CO2) MSCs
(named as NP-MSCs) were used as a control.
Semiquantitative RT-PCR analysis
Total RNA was extracted from bone marrow mononuclear cells
(BMMCs) and bone marrow-derived MSCs using Trizol reagents
(Invitrogen Life Technologies) according to manufacturer’s
instructions. The sequence of primers for PCR was as follows:
CXCR4, 59-AAAGCTAGCCGTGATCCTCA-39 (sense) and 59-
CACCATTTCAGGCTTTGGTT -39 (anti-sense); CXCR7, 59-
TCACCTACTTCACCGGCACC-39 (sense) and 59-ACAT-
GGCTCTAGCGAGCAGG-39 (anti-sense); SDF-1a,5 9-AAAC-
CAGTCAGCCTGAGCTAC-39 (sense) and 59-TTACTTGTT-
TAAAGCTTTCTC-39 (anti-sense); GAPDH, 59-ACCACAGTC-
CATGCCATCAC-39 (sense) and 59-TCCACCACCCTGTT-
GCTGTA-39 (anti-sense). The PCR conditions were as follows:
denaturation at 94uC for 30 s, annealing at 60–62uC for 30 s, and
extension at 72uC for 30 s, which was repeated for 35 cycles. The
PCR amplicons were then separated on 2.0% agarose gel by
electrophoresis and analyzed by densitometry.
Western blots
BMMCs and MSCs were washed with ice-cold PBS and
scraped in RIPA lysis buffer including protease inhibitors. After
loaded and separated on sodium dodecyl sulphate polyacrylamide
gel (SDS–PAGE), the proteins were electrophoretically transferred
onto a polyvinylidene difluoride membrane and then blocked with
16TBS plus Tween 20 (TBST) containing 5% nonfat dry milk for
2 h at room temperature. The membrane was incubated overnight
at 4uC with SDF-1a (eBioscience, 1:1000), CXCR4 (Santa-Cruz
Biotechnology, 1:250), CXCR7 (R&D Systems, 1:200) or b-actin
(Abcam, 1:2000) antibodies appropriately diluted in 16TBST
containing 5% nonfat dry milk. The immune complexes were
visualized with appropriate horseradish peroxidase-conjugated
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(Amersham, Freiburg, Germany).
ELISA
The production of SDF-1a, VEGF, b-FGF, IGF-1, and HGF in
the supernatants of MSCs and in the kidney cortex was
determined by ELISA using a commercially available ELISA kit
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s recommendation. Supernatants were prepared by
collecting serum-free DMEM medium after 24 hour culture of
approximately 1610
6 MSCs under normoxia or hypoxia.
Decapsulated kidney cortex tissues were retrieved before (n=10)
and 0.5, 1, 3, 5, 7, 14 days after I/R (n=10) and cell and tissue
lysates were obtained by mincing, sonicating, and lysing with
RIPA buffer. Protein was quantified by BCA protein assay reagent
assay (Pierce, Rockford, IL, USA). Optical density was measured
at 450 nm with wavelength correction at 570 nm. All samples and
standards were measured in duplicate. In some experiments,
MSCs were pretreated with SDF-1a (50 ng/ml), a neutralizing
anti-CXCR4 antibody (10 mg/ml, Clone 247506, Rat IgG2B,
R&D Systems), rat IgG2B isotype control (10 mg/ml, Clone
141945, R&D Systems), an anti-CXCR7 antibody (10 mg/ml,
Catalog number AF4227, sheep IgG, R&D Systems), or a sheep
IgG isotype control (10 mg/ml, Catalog number 5-001-A, R&D
Systems).
Chemotaxis assay
The transwell system was purchased from Millipore Inc
(Billerica, MA). Briefly, SDF-1a (10 ng/ml, Millipore, Billerica,
MA) was placed in the lower chamber, and 10
5 cells were added to
the upper chamber in the presence or absence of a neutralizing
anti-CXCR4 antibody, an anti-CXCR7 antibody, a rat IgG2B
isotype control antibody, or a sheep IgG isotype control antibody
(all at a concentration of 10 mg/ml). The chemotaxis chambers
were then incubated for 12 h at 37uC. Then, non-migrating cells
were removed from the top chamber, and migrated cells were
fixed in methanol and stained with 2% toluidine. The number of
cells that had migrated through to the underside of the insert
membranes was calculated by counting at least five random
separate fields (400-fold magnification).
In some experiments, primary renal tubule epithelial cells
(TECs) from 1–2-week-old C56BL/6-mice were cultured in
serum-free DMEM and exposed to sublethal hypoxia for 6 h
(,3% O2) followed by 12 h of reoxygenation (21% O2). After
hypoxia/reoxygenation (H/R) the cells were washed twice and
added in the lower chamber for the transfilter assay. Primary
mouse proximal TECs were generated as previously described
[53]. Kidney medulla was discarded, kidney cortices was minced
and digested with collagenase I (Sigma Chemical Co.). The cell
suspensions were filtered through 40 mm strainers (BD Falcon
2350; BD Pharmingen, San Diego, CA, USA) and seeded on
Nunclon–treated 6-well plates (Nalgene/Nunc International,
Rochester, NY). Once confluent and prior to use, the epithelial
nature of the cells was characterized by positive staining for
megalin and aquaporin-1 (Santa Cruz Biotechnology, Inc.).
Cell viability and cytotoxicity assays
Cells in the dish (10
5 cells/well) were cultured with SDF-1a
(50 ng/ml) or SDF-1a plus H2O2 (250 mM, Sigma-Aldrich) for
6 h in presence or absence of a neutralizing anti-CXCR4
antibody, an anti-CXCR7 antibody, a rat IgG2B isotype control
antibody, or a sheep IgG isotype control antibody (all at a
concentration of 10 mg/ml). The following standard cytotoxicity
tests were performed as described [54]. The viability of the cells
was measured using both 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphe-
nyl-2H-tetrazolium bromide (MTT) assay and an automated cell
counter (NucleoCounter, New Brunswick Scientific, Edison, NJ).
The cell counter technique uses propidium iodide (PI), which
binds to cellular nuclei. Depending on sample preparation, the
counts provide the total number of cells or viable cells. Cytotoxicty
was also determined by measuring the amount of lactate
dehydrogenase (LDH) released in the cell culture medium using
a Sigma assay kit by measuring absorption at 340 nm.
Transient cell transfection
The NP-MSCs that had undetectable CXCR4 and CXCR7
expression were transfected using pORF9-mCXCR4 (an expres-
sion vector containing the mouse CXCR4 open-reading frame) or
pORF9-mCXCR7 (an expression vector containing the mouse
CXCR7 open-reading frame), respectively (InvivoGen, CA, USA).
Figure 7. The effects of SDF-1-CXCR4/CXCR7 pathway on the therapeutic efficacy of HP-MSCs for treatment of I/R-AKI. (A and B) BUN
(A) and Scr (B) levels as measured in I/R-AKI mice received HP-MSCs, NP-MSCs or vehicle (DMEM). *P,0.05 vs DMEM;
{P,0.05 vs NP-MSCs. (C) The
histological score of kidney (HSK) in I/R-AKI mice received HP-MSCs, NP-MSCs or vehicle, respectively, was calculated. *P,0.05 vs DMEM;
{,0.05 vs
NP-MSCs. (D and E) HP-MSC-treated mice showed a significantly earlier rise in proliferating cells (D), and simultaneous reduction of number of
apoptotic cells compared with NP-MSC-treated mice (E). *P,0.05 vs DMEM;
{P,0.05 vs NP-MSCs;
{P,0.05 vs pre-transplantation. (F through J) BUN
levels (F), Scr levels (G), HSK (H), renal PCNA expression (I), and renal TUNEL-apoptosis (J) were evaluated in mice treated with HP-MSCs+IgG2B-isotype
control antibody, HP-MSCs+anti-CXCR4 antibody, HP-MSCs+IgG-isotype control antibody, and HP-MSCs+anti-CXCR7 antibody, respectively. *P,0.05,
vs the respective isotype-matched control antibodies.
doi:10.1371/journal.pone.0034608.g007
Figure 8. A model of regenerative potential of HP-MSCs in
repair of I/R-AKI. Chemokine SDF-1 expression is upregulated in
postischemic kidneys. HP enhances the expression of both SDF-1
receptors, CXCR4 and CXCR7, in MSCs. Intravenously injected HP-MSCs
are recruited to the ischemic kidney and localized within the injured
capillaries and in the interstitium through SDF-1a-CXCR4 interaction.
The binding of SDF-1 to both CXCR4 and CXCR7 is responsible for the
production of paracrine mediators, including VEGF, b-FGF, IGF-1 and
HGF that exert mitogenic, anti-apoptotic, pro-angiogenic, and anti-
inflammatory effects.
doi:10.1371/journal.pone.0034608.g008
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from the ATG to the stop codon. The ORF size was 1089 bp and
the cloning fragment size was 1069 bp for mCXCR4 or 1203 bp
for mCXCR7. The protocol for growth of pORF-transformed
bacteria and the selection of bacterial clones has been previously
described [55]. Briefly, the lyophilized E.coli were resuspended
with 1 ml of LB medium and streaked onto ampicillin LB agar
plate prepared with the E. coli Fast-Media Amp agar and
incubated at 37uC overnight. Isolated single colony of the bacteria
was grown in TB medium supplemented with ampicillin using the
Fast-Media Amp liquid overnight at 37uC. The pORF plasmid
DNA was extracted using the QUIAGEN plasmid midi kit
(Quiagen, USA) and the yield was measured spectrophotometri-
cally. For each transfection, NP-MSCs (2610
6) were plated in one
well of 6-well plates and grown in DMEM containing 10% FBS
until cell density reached 75% confluence. The expression plasmid
DNA [15 mg in 800 ml of opti-MEM medium (Gibco, USA)] was
mixed with 15 ml lipofectAMINE (Gibco, USA) and incubated at
room temperature for 30 min. The MSCs were washed with
serum-free medium, mixed with lipofectAMINE/DNA mixture
and incubated at 37uC for 5 h and for a further 48 h in the
presence of growth medium containing 20% FBS. As a control,
NP-MSCs were similarly transfected with an empty vector
(pORF9-MCS, Invivogen, CA, USA). In each experiment, the
transfection efficiency was assessed using Western blots of
transfected and identically treated non-transfected cells. The
transfection efficiency ranged from 74–82% and the viability, as
assessed by trypan blue dye exclusion, ranged between 90 and
97%. These cells were further used to investigate the functional
characteristics of CXCR4- or CXCR7-transfected NP-MSCs in
chemotaxis assay, ELISA assay of secreted VEGF, b-FGF, IGF-1
and HGF, cell viability and cytotoxicity assays.
Induction of I/R-AKI
Models of I/R-AKI were performed in female 6–8-week-old
C57BL/6 mice by clamping both renal pedicles for 30 minutes
followed by clamp release to allow reperfusion as described earlier
[56]. To ensure complete intravenous administration of MSCs, a
27G canula connected to a short polyethylen-catheter was used. At
24 h after surgery, the cells (1610
6/0.5 ml L-DMEM) were
infused via the cannulated tube that was then flushed with 0.3 ml
L-DMEM in order to infuse cells remaining in the tubing. In order
to be able to detect the homing of MSCs to the target tissue, MSCs
were labeled with
111Indium-oxine (GE Healthcare).
The animal were randomly assigned to one of seven
experimental groups (n=10) as follows: group 1, serum-free L-
DMEM; group 2,
111Indium-labeled NP-MSCs; group 3,
111Indium-labeled HP-MSCs; group 4,
111indium-labeled HP-
MSCs pretreated with IgG2B isotype control antibody; group 5,
111Indium-labeled HP-MSCs pretreated with a neutralizing anti-
CXCR4 antibody; group 6,
111Indium-labeled HP-MSCs pre-
treated with IgG isotype control antibody; and group 7,
111Indium-labeled HP-MSCs pretreated with a neutralizing anti-
CXCR7 antibody. Pretreatment of cells with neutralizing
antibodies (10 mg/10
6cells) was performed by incubating for
30 min on ice.
In vitro labeling and in vivo homing of transplanted MSCs
Radiotracer labeling of MSCs is simpler than fluorescent
labeling, and the traced MSCs can be quantified accurately in
tissue. Therefore, the radioactive
111Indium was used to label
MSCs in this study. The cultured MSCs at passage 3 were
incubated with radioactive
111Indium (100 mCi/10
6 cells) for
15 min at room temperature. After repeated centrifugation and
wash to assure clearance of any unbound radioactivity, the
efficiency of
111Indium-radiolabeling MSCs was measured as
about 80%, resulting in a specific activity of approximately
80 mCi/10
6 cells. Preliminary experiments showed that the
viability and growth of these labeled MSCs were not adversely
affected by this labeling procedure (data not shown). Three hours
and 1, 2, 3, 5, 7 and 14 days after MSC transplantation, mice were
euthanized with an overdose of pentobarbital and the organs,
including kidneys, lungs, heart, spleen and liver, were excised and
weighed. Biometric data (body weight and organ weight) of the
mice allocated to seven different treatment groups revealed no
significant difference (P.0.05, data not shown). The radioactivity
in each organ was measured using a gamma scintillation counter
and adjusted by the half-life of
111Indium (2.8 days). To facilitate
comparisons, specific tissue distribution of the transplanted MSCs
was expressed as the percentage of injected dose per gram of tissue
(%ID/g) and percentage injected dose per organ (%ID/organ).
HSK
The excised kidneys were fixed in phosphate-buffered 10%
formalin, sectioned, and then stained with hematoxylin and eosin.
Evaluation of histological score of kidney (HSK) was performed in
a blind manner by a pathologist. HSK was graded on a 4-point
scale [57]: 0=normal histology; 1=mild damage [less than one-
third of nuclear loss (necrosis) per tubular cross section];
2=moderate damage [greater than one-third and less than two-
thirds of tubular cross section showing nuclear loss (necrosis)];
3=severe damage [greater than two-thirds of tubular cross section
shows nuclear loss (necrosis)]. The total score per kidney section
was calculated by addition of all 10 scores with a maximum
possible injury score of 30.
Immunohistochemical staining
The tissue sections were subject to immunohistochemical
staining for SDF-1a and proliferating cell nuclear antigen (PCNA)
immediately and 1, 2, 3 and 7 days after cell transplantation. For
immunohistochemical staining, the rabbit specific horseradish
peroxidase-diaminobenzidine (HRP-DAB) detection immunohis-
tochemical kit (ab64261, Abcam) was used. Briefly, after
deparaffination, four micron sections of kidneys were hydrated
by decreasing concentrations of ethanol and incubated with a
peroxidase-blocking reagent for 30 min. Before immunostaining,
sections for SDF-1a staining were treated with 0.1 mol/L sodium
citrate buffer (pH 6.0) in a microwave oven for antigen retrieval.
Sections were incubated overnight at 4uC with the primary
antibodies, a rabbit polyclonal SDF-1a antibody (1:200,
eBioscience, San Diego, CA, USA) and a rabbit polyclonal FL-
261 antibody (1:200, sc-7907, Santa Cruz Biotechnology, Santa
Cruz, USA). Control experiments included omission of either the
primary or secondary antibody. The reaction sections were
incubated with biotinylated goat anti rabbit IgG(H+L) as a
secondary antibody for 10 min. Visualization of the specific
binding on the sites of primary antibodies was developed by an
enzymatic conversion of the DAB into a brown precipitate by
streptavidin peroxidase. After counterstaining with hematoxylin,
the sections were mounted, cleared, and coverslipped. The
number of PCNA-positive cells, a marker of mitogenesis, was
carried out by counting the number of positive nuclei in 10
randomly selected sections of kidney cortex and outer medulla,
and converted to the mean number of positive cells in high-power
fields (HPF, 620 magnification). Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay was
performed according to the manufacturer’s instructions (In Situ
Cell Death Detection Kit; Roche China, Ltd.) to detect tubular
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were screened for positive nuclei under a fluorescence microscope,
and 10 random fields in the corticomedullary area were counted
for every kidney at 640 magnification.
Statistical Analysis
Each experiment was repeated at least ten times. All values are
given as mean 6SD. Student’s t test and one-way ANOVA of
variance followed by Dunnett’s multiple comparison tests were
adopted for all statistical data. All analyses were carried out using
SPSS 11.0 software (Chicago, IL, USA). P,0.05 was considered
statistically significant.
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